Clinical Trials for Kidney Cancer

Phase 2, Open-label, Single Cohort, Multicenter Trial for Sequential Treatment of High Dose Cabozantinib on/After Progression on Cabozantinib Monotherapy in Advanced Renal Cell Carcinoma (Seq-Cabo)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable or metastatic RCC of any histology who previously benefited from and then progressed on cabozantinib 60 mg daily receive cabozantinib dose escalation to 80 mg daily. Cabozantinib is a multikinase inhibitor targeting VEGFR, MET, and AXL; prior PD-1/PD-L1 therapy is allowed, and participants must have measurable disease and ECOG 0–2.

ClinicalTrials.gov ID: NCT05931393

Pilot Study of an Implantable Microdevice for in Situ Evaluation of Drug Response in Renal Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with suspected or confirmed metastatic RCC undergoing standard-of-care nephrectomy or metastasectomy receive a percutaneously placed implantable microdevice 72±24 hours pre-op that releases microdoses of up to 19 anticancer agents locally into the tumor to assess in situ drug response; the device and surrounding tissue are removed at surgery. Investigational component is the microdevice-based response profiling (not therapeutic), using FDA-approved or RCC-relevant agents (e.g., TKIs, IO, targeted therapies) to inform sensitivity.

ClinicalTrials.gov ID: NCT05700461

A Phase II Study Assessing the Feasibility and Clinical Efficacy of Adaptive Immunotherapy Combination With VEGFR-TKI in Patients With Advanced Renal Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Treatment-naïve adults with unresectable/metastatic clear cell RCC (ECOG 0–2) receive pembrolizumab (PD‑1 inhibitor) plus axitinib (VEGFR‑1/2/3 TKI) with an adaptive on–off dosing strategy triggered by RECIST responses on serial imaging. Excludes active CNS disease unless treated/stable and significant recent cardiovascular events; controlled HBV/HCV/HIV allowed.

ClinicalTrials.gov ID: NCT06860386

Phase II Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic renal cell carcinoma on a stable immune checkpoint inhibitor regimen who develop 1–5 oligoprogressive lesions receive SBRT to all progressing sites (with optional local therapies to some lesions) while continuing the same ICI. Excludes brain-only progression; aims to prolong disease control without switching systemic therapy.

ClinicalTrials.gov ID: NCT04974671

Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with oligometastatic renal cell carcinoma (2–5 measurable lesions; primary controlled; IMDC favorable/intermediate; ECOG 0–2) are randomized to stereotactic ablative radiotherapy to all metastases followed by standard systemic therapy versus standard systemic therapy alone. Systemic options per guideline may include immune checkpoint inhibitors and/or VEGF/tyrosine kinase inhibitors; key exclusions include brain metastases, sarcomatoid component, and prior systemic therapy for metastatic disease.

ClinicalTrials.gov ID: NCT05863351

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors eligible for on-label PD-1 therapy (nivolumab or pembrolizumab) are randomized in a crossover design to receive standard PD-1 inhibitors via subcutaneous versus intravenous administration, assessing patient/clinician preference, satisfaction, QoL, safety, and selected clinical outcomes. Includes PD-(L)1–naïve patients or those willing to switch; excludes prior severe hypersensitivity and transplant history.

ClinicalTrials.gov ID: NCT07223424

An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients with Select Solid Tumors.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: This clinical trial evaluates the safety and efficacy of the investigational drug NEO212, a novel conjugate of temozolomide and perillyl alcohol with enhanced brain penetration, in adults with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, or uncontrolled brain metastases from select solid tumors, including combinations with standard treatments like pembrolizumab or ipilimumab.

ClinicalTrials.gov ID: NCT06047379

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using Interleukin-15 And -21 Armored Glypican-3-Specific Chimeric Antigen Receptor Expressing Autologous T Cells

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with GPC3-positive solid tumors (notably HCC; centrally confirmed by IHC) after standard therapies receive autologous GPC3-targeted CAR T cells armored with IL-15 and IL-21 to enhance expansion/persistence, incorporating an inducible caspase-9 safety switch, following cyclophosphamide/fludarabine lymphodepletion. Optional second infusion at 4 weeks if no progression.

ClinicalTrials.gov ID: NCT06198296

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as an Immunotherapy for Children With Solid Tumors (CARE)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Children and young adults (1–21 years) with relapsed/refractory GPC3-positive solid tumors (including HCC) receive cyclophosphamide/fludarabine lymphodepletion followed by a single infusion of autologous GPC3-targeted CAR T cells co-expressing IL-15 and IL-21, with an inducible caspase-9 safety switch. The investigational CAR targets the tumor proteoglycan GPC3, with IL-15/IL-21 “armoring” intended to enhance T-cell expansion and persistence.

ClinicalTrials.gov ID: NCT04715191

Phase 2 Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Maintenance cabozantinib (oral multi-kinase inhibitor of MET/VEGFR2/AXL/RET) for 12 months in children, adolescents, and young adults (≥18 months to <40 years) with ultra–high-risk solid tumors who have achieved at least stable disease after their most recent therapy and can start within 12 weeks. Includes strata such as neuroblastoma, metastatic Ewing sarcoma, osteosarcoma, high-risk rhabdomyosarcoma, DSRCT, and other high-risk sarcomas; single-arm, compared to historical controls.

ClinicalTrials.gov ID: NCT05135975